<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710435</url>
  </required_header>
  <id_info>
    <org_study_id>022-REDUCLN-001</org_study_id>
    <nct_id>NCT02710435</nct_id>
  </id_info>
  <brief_title>REDUCER-I: An Observational Study of the Neovasc Reducer™ System</brief_title>
  <official_title>REDUCER-I: An Observational Study of the Neovasc Reducer™ System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovasc Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovasc Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect long term data of the Neovasc Reducer System in
      subjects with refractory angina pectoris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, multi-country three-arm prospective and retrospective
      investigation in up to 400 subjects conducted at a maximum of 40 investigational centers. Arm
      1 will include eligible prospective subjects. Arm 2 will include subjects who were previously
      enrolled and treated with the Reducer during the COSIRA (Coronary Sinus Reducer for Treatment
      of Refractory Angina) study. Arm 3 will include subjects who received a Reducer under CE Mark
      (unrelated to the COSIRA study).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Canadian Cardiovascular Society (CCS) Grade</measure>
    <time_frame>6 Months</time_frame>
    <description>The percentage of subjects who experience improvement in their angina symptoms defined as a reduction in CCS grade, at 6 months as compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Occurrence of Device and/or Procedure Related Peri-Procedural Serious Adverse Events (SAE)s</measure>
    <time_frame>30 days post implant</time_frame>
    <description>The rate of occurrence of device and / or procedure-related periprocedural SAEs defined as a composite of death, Myocardial Infarction (MI), cardiac tamponade, clinically-driven re-dilation of a Reducer, life-threatening arrhythmias (Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF)), and respiratory failure through 30 days post-implant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>30 days post implant</time_frame>
    <description>Major Adverse Cardiac Events (MACE): a composite of cardiac death, major stroke, and MI through 30-days post-implant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in Canadian Cardiovascular Society (CCS) Grade</measure>
    <time_frame>12 months and annually through 5 years</time_frame>
    <description>The percentage of subjects who experience improvement in their angina symptoms defined as a reduction in CCS grade at 12 months and annually through 5 years post implant as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>6 months, 12 months, and annually through 5 years</time_frame>
    <description>Major Adverse Cardiac Events (MACE): a composite of cardiac death, major stroke, and MI at 6 months, 12 months and annually through 5 years post implant</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Exercise Tolerance Test (ETT) Parameters</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>The change in ETT parameters at 6 and 12 months post implant as compared to baseline: Total exercise duration (min), Time to 1mm ST-Segment Depression (min), METs, Double Product by ETT</description>
  </other_outcome>
  <other_outcome>
    <measure>Improvement in Quality of Life (QoL</measure>
    <time_frame>6 months, 12 months, and annually through 5 years</time_frame>
    <description>Improvement in QoL scores at 6 months, 12 months and annually through 5 years post implant as compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in Emergency Department Visits</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction in documented Emergency Department visits due to angina episodes at 12 months post implant as compared to 12 months prior to implantation of the Reducer</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in Angina Medication</measure>
    <time_frame>6 months, 12 months, and annually through 5 years</time_frame>
    <description>Reduction in angina medication use at 6 months, 12 months and annually through 5 years post implant as compared to baseline</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Angina Pectoris</condition>
  <condition>Angina Pectoris, Stable</condition>
  <condition>Chronic Stable Angina</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Prospective</arm_group_label>
    <description>Includes eligible subjects in the prospective arm who undergo baseline testing followed by the Neovasc Reducer System implant procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - COSIRA</arm_group_label>
    <description>Includes subjects who were previously enrolled and treated with the Neovasc Reducer System during the COSIRA study and agree to participate in this long term follow up study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - CE Mark</arm_group_label>
    <description>Includes subjects who received a Neovasc Reducer System under CE Mark (unrelated to the COSIRA study), and agree to participate in this long term follow up study
Arm 3 has been closed to enrollment-June 2017</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neovasc Reducer System</intervention_name>
    <description>An aid in the management of chronic refractory angina pectoris</description>
    <arm_group_label>Arm 1 - Prospective</arm_group_label>
    <arm_group_label>Arm 2 - COSIRA</arm_group_label>
    <arm_group_label>Arm 3 - CE Mark</arm_group_label>
    <other_name>Reducer</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with refractory angina pectoris who demonstrate objective evidence of reversible
        myocardial ischemia, who have limited or no options for revascularization, or subjects who
        have received the Reducer in the COSIRA study, or under CE Mark prior to the REDUCER-I
        study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria - ALL Arms:

          -  Subject has been informed about the study and provides written informed consent prior
             to enrollment

          -  Subject is willing to comply with specified follow-up evaluations

        Inclusion Criteria - Arm 1:

          -  Symptomatic Coronary Artery Disease (CAD) with chronic refractory angina pectoris
             despite attempted optimal medical therapy

          -  Subject has limited treatment options for revascularization by Coronary Artery Bypass
             Grafting (CABG) or by Percutaneous Coronary Intervention (PCI)

          -  Evidence of reversible myocardial ischemia

          -  Left Ventricular ejection fraction (LVEF) greater than or equal to 30%

          -  Male or non-pregnant female

        Inclusion Criteria - Arm 2:

          -  Subjects previously implanted in the Reducer (treatment) arm of the COSIRA study

        Inclusion Criteria - Arm 3:

          -  Subjects in whom the Reducer was implanted under CE Mark (unrelated to the COSIRA
             study), prior to enrollment in the Reducer-I study

        Exclusion Criteria - Arm 1:

          -  Recent (within three months) acute coronary syndrome

          -  Recent (within six months) PCI or CABG

          -  Unstable angina during the 30 days prior to baseline

          -  Decompensated congestive heart failure (CHF) or hospitalization due to CHF during the
             three months prior to baseline

          -  Life threatening rhythm disorders or any rhythm disorders that would require placement
             of an internal defibrillator and / or pacemaker

          -  Severe chronic obstructive pulmonary disease (COPD)

          -  Subject cannot undergo exercise tolerance test or 6-minute walk test for reasons other
             than refractory angina

          -  Severe valvular heart disease

          -  Subject with pacemaker or defibrillator electrode in the right atrium (RA), right
             ventricle (RV), or Coronary Sinus (CS)

          -  Subject having undergone tricuspid valve replacement or repair

          -  Chronic renal failure including subjects on chronic hemodialysis

          -  Moribund subjects, or subjects with comorbidities limiting life expectancy to less
             than one year

          -  Known allergy to stainless steel or nickel

          -  Currently enrolled in another device or drug trial that has not completed the primary
             endpoint or that clinically interferes with the current study endpoints

        Angiographic Exclusion:

          -  Mean right atrial pressure greater than or equal to 15mmHg

          -  Subject with anomalous or abnormal CS as demonstrated by angiogram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Verheye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZNA Middelheim Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen A Cook</last_name>
    <phone>855.802.5180</phone>
    <phone_ext>307</phone_ext>
    <email>kcook@neovasc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naomi Tatarek</last_name>
    <phone>855.802.5180</phone>
    <phone_ext>301</phone_ext>
    <email>ntatarek@neovasc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ZNA Middelheim Hospital</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Jacobs</last_name>
      <email>christine.jacobs@zna.be</email>
    </contact>
    <investigator>
      <last_name>Stefan Verheye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zienkenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Swijsen</last_name>
      <email>Caroline.Swijsen@zol.be</email>
    </contact>
    <investigator>
      <last_name>Matthias Dupont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Kisselbach</last_name>
      <email>c.kisselbach@kerckhoff-forschungs-gmbh.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Liebetrau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Contilia Heart and Vascular Centre, Elisabeth Krankenhaus Essen, Klinik fϋr Kardiologie und Angiologie</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Huening</last_name>
      <email>v.huening@contilia.de</email>
    </contact>
    <investigator>
      <last_name>Christopher Naber, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Heart Center Freiburg - Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Stein</last_name>
      <email>miriam.stein@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Constantin von zur Muehlen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Giesen</name>
      <address>
        <city>Giesen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Kelm</last_name>
      <email>christiane.kelm@innere.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Holger Nef, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Redlefsen</last_name>
      <email>m.redlefsen@uke.de</email>
    </contact>
    <investigator>
      <last_name>Ulrich Schaefer, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lukaskrankenhaus Neuss</name>
      <address>
        <city>Neuss</city>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Roettgen</last_name>
      <email>jroettgen@lukasneuss.de</email>
    </contact>
    <investigator>
      <last_name>Hubertus Degen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vega Rusconi</last_name>
      <email>rusconi.vega@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bolognini General Hospital</name>
      <address>
        <city>Seriate</city>
        <zip>24068</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florinda Maiorana</last_name>
      <email>florindamaiorana@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alfonso Ielasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Rost</last_name>
      <email>i.rost@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Pierfrancesco Agostoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Vlaardingerbroek</last_name>
      <email>k.vlaardingerbroek@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Leo Timmers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Jordan</last_name>
      <phone>+41 61 556 5703</phone>
      <email>Franziska.jordan@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Kaiser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HFR Fribourg/University of Fribourg</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Lehman</last_name>
      <email>Sonja.Lehmann@h-fr.ch</email>
    </contact>
    <investigator>
      <last_name>Stephane Cook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Camporini</last_name>
      <email>cristina.camporini@cardiocentro.org</email>
    </contact>
    <investigator>
      <last_name>Tiziano Moccetti, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Atkinson</last_name>
      <email>Ward22.Research@bthft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Steven Lindsay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belinda Rif</last_name>
      <email>belinda.rif@nhslothian.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Miles Behan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Arnold</last_name>
      <email>sophie.arnold@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Simon Redwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Andrews</last_name>
      <email>michelle.andrews1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Jonathan Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Dempster</last_name>
      <email>d.dempster@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ranil De Silva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.neovasc.com/products/neovasc-reducer/</url>
    <description>Company product webpage</description>
  </link>
  <reference>
    <citation>Banai S, Ben Muvhar S, Parikh KH, Medina A, Sievert H, Seth A, Tsehori J, Paz Y, Sheinfeld A, Keren G. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol. 2007 May 1;49(17):1783-9.</citation>
    <PMID>17466229</PMID>
  </reference>
  <reference>
    <citation>Banai S, Verheye S, Jolicoeur EM. A device to narrow the coronary sinus for angina. N Engl J Med. 2015 May 14;372(20):1967-8. doi: 10.1056/NEJMc1503672.</citation>
    <PMID>25970058</PMID>
  </reference>
  <reference>
    <citation>Verheye S, Jolicœur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, Vrolix M, Agostoni P, Engstrom T, Labinaz M, de Silva R, Schwartz M, Meyten N, Uren NG, Doucet S, Tanguay JF, Lindsay S, Henry TD, White CJ, Edelman ER, Banai S. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015 Feb 5;372(6):519-27. doi: 10.1056/NEJMoa1402556.</citation>
    <PMID>25651246</PMID>
  </reference>
  <reference>
    <citation>Konigstein M, Verheye S, Jolicœur EM, Banai S. Narrowing of the Coronary Sinus: A Device-Based Therapy for Persistent Angina Pectoris. Cardiol Rev. 2016 Sep-Oct;24(5):238-43. doi: 10.1097/CRD.0000000000000101. Review.</citation>
    <PMID>26886464</PMID>
  </reference>
  <reference>
    <citation>Abawi M, Nijhoff F, Stella PR, Voskuil M, Benedetto D, Doevendans PA, Agostoni P. Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience. Neth Heart J. 2016 Sep;24(9):544-51. doi: 10.1007/s12471-016-0862-2.</citation>
    <PMID>27299456</PMID>
  </reference>
  <reference>
    <citation>Konigstein M, Meyten N, Verheye S, Schwartz M, Banai S. Transcatheter treatment for refractory angina with the Coronary Sinus Reducer. EuroIntervention. 2014 Feb;9(10):1158-64. doi: 10.4244/EIJV9I10A196.</citation>
    <PMID>24561732</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Sinus</keyword>
  <keyword>Reducer</keyword>
  <keyword>Refractory Angina</keyword>
  <keyword>Angina Pectoris</keyword>
  <keyword>Angina Pectoris, Stable</keyword>
  <keyword>Chronic Stable Angina</keyword>
  <keyword>Persistent Angina</keyword>
  <keyword>Neovasc Reducer System</keyword>
  <keyword>Refractory Angina Pectoris</keyword>
  <keyword>Coronary Sinus Narrowing</keyword>
  <keyword>Reversible Ischemic Heart Disease</keyword>
  <keyword>Chronic Angina</keyword>
  <keyword>End Stage Angina</keyword>
  <keyword>Coronary Sinus Reduction</keyword>
  <keyword>Coronary Sinus Reducer</keyword>
  <keyword>Chronic Refractory Angina</keyword>
  <keyword>Chronic Refractory Angina Pectoris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

